Clinical Trial Update: Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a dendritic cell-based treatment combined with immunotherapy for metastatic or unresectable triple-negative breast cancer has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer
• Unresectable Triple-negative Breast Cancer

Drugs mentioned

• Dendritic cell-based therapy with immunotherapy

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Status: WITHDRAWN